Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 03, 2009 | Chief Operating Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 54,000 | -- | 54,000 | |
| Feb 03, 2009 | SVP, HR & Leadership Devt | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 31,500 | -- | 31,500 | |
| Feb 03, 2009 | VP, Clinical Research | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 18,000 | -- | 18,000 | |
| Feb 11, 2009 | Director | Open market or private sale of non-derivative or derivative security | Form 4 | 1,839 | $9.42 | 1,652,390 | |
| Feb 11, 2009 | Director | Open market or private sale of non-derivative or derivative security | Form 4 | 69 | $9.42 | 61,700 | |
| Mar 01, 2009 | Chief Financial Officer | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Form 4 | 220 | $8.06 | 33,615 | |
| Mar 11, 2009 | Director, President & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 1,000 | $5.33 | 119,736 | |
| Mar 11, 2009 | Director, President & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 1,000 | -- | 89,000 | |
| Mar 19, 2009 | Sr VP, Technical Operations | Open market or private sale of non-derivative or derivative security | Form 4 | 229 | $10.00 | 46,311 | |
| Mar 23, 2009 | Sr VP, Technical Operations | Open market or private sale of non-derivative or derivative security | Form 4 | 1,740 | $10.00 | 44,571 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.